TGTX Stock Summary and Trading Ideas (TG Therapeutics | NASDAQ:TGTX)

TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). and the company is developing TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders which are under Phase 1 trial.

TG Therapeutics trades on the NASDAQ stock market under the symbol TGTX.

As of April 18, 2024, TGTX stock price climbed to $13.99 with 3,252,143 million shares trading.

TGTX has a beta of 3.23, meaning it tends to be more sensitive to market movements. TGTX has a correlation of 0.12 to the broad based SPY ETF.

TGTX has a market cap of $2.12 billion. This is considered a Mid Cap stock.

Last quarter TG Therapeutics reported $44 million in Revenue and -$.09 earnings per share. This beat revenue expectation by $4 million and exceeded earnings estimates by $.01.

In the last 3 years, TGTX stock traded as high as $45.50 and as low as $3.48.

The top ETF exchange traded funds that TGTX belongs to (by Net Assets): VTI, XBI, VB, IWM, VXF.

TGTX has underperformed the market in the last year with a return of -31.9%, while the SPY ETF gained +22.3%. In the last 3 month period, TGTX fell short of the market, returning -8.6%, while SPY returned +6.1%. However, in the most recent 2 weeks TGTX has outperformed the stock market by returning -3.3%, while SPY returned -3.8%.

TGTX support price is $13.44 and resistance is $14.20 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that TGTX stock will trade within this expected range on the day.